Neutrophil CD64 a Diagnostic and Prognostic Marker of Sepsis in Adult Critically Ill Patients: A Brief Review.
Fc receptor 1
Immunoglobulin-G
Neutrophil CD64
Sepsis
Septic shock
Journal
Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine
ISSN: 0972-5229
Titre abrégé: Indian J Crit Care Med
Pays: India
ID NLM: 101208863
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
entrez:
15
1
2021
pubmed:
16
1
2021
medline:
16
1
2021
Statut:
ppublish
Résumé
Sepsis is a life-threatening organ dysfunction with increased incidence of morbidity and mortality. Early diagnosis and prompt therapeutic intervention is the cornerstone of sepsis care. Biomarkers play an important role in sepsis having both diagnostic and prognostic implications. Neutrophil CD64 (nCD64) is a useful candidate biomarker for sepsis. Neutrophil CD64 also known as Fc receptor 1 (FcR1), is a high-affinity receptor present on neutrophils for Fc part of immunoglobulin-G (IgG) heavy chain. Its expression gets strongly upregulated in response to proinflammatory cytokines of infection within 4-6 hours. Neutrophil CD64 integrates function involving both innate and adaptive immune responses. The aim of this review is to present literature about nCD64 as a diagnostic and prognostic marker in patients with sepsis/septic shock. The authors searched articles over 13 years, i.e., from 2006 to 2019. They included articles written in English only and further reviewed the reference list of selected articles to obtain potentially relevant articles. Reviews, letters, commentaries, correspondences, case reports, conference abstracts, expert opinions, editorials, and animal experiments were excluded. Articles involving pediatric patients (≤18 years) were also excluded. Several studies have indicated that nCD64 is a highly sensitive and specific marker for the diagnosis of sepsis. Various combinations of biomarkers have been used with nCD64 for a better diagnostic value. Neutrophil CD64 as a prognostic marker in critically ill patients needs to be explored more. Most of the existing literatures have highlighted its prognostic utility based on single value at enrolment. There are limited literatures on prognostic implications of serial trend and kinetics of nCD64. Neutrophil CD64 is a useful diagnostic and prognostic marker of sepsis in critically ill patients. Additional studies are needed on nCD64 in sepsis based on sepsis-3 criteria. Further trials with large sample size are needed to establish prognostic implications of serial nCD64 trend. Patnaik R, Azim A, Agarwal V. Neutrophil CD64 a Diagnostic and Prognostic Marker of Sepsis in Adult Critically Ill Patients: A Brief Review. Indian J Crit Care Med 2020;24(12):1242-1250.
Sections du résumé
INTRODUCTION
BACKGROUND
Sepsis is a life-threatening organ dysfunction with increased incidence of morbidity and mortality. Early diagnosis and prompt therapeutic intervention is the cornerstone of sepsis care. Biomarkers play an important role in sepsis having both diagnostic and prognostic implications. Neutrophil CD64 (nCD64) is a useful candidate biomarker for sepsis. Neutrophil CD64 also known as Fc receptor 1 (FcR1), is a high-affinity receptor present on neutrophils for Fc part of immunoglobulin-G (IgG) heavy chain. Its expression gets strongly upregulated in response to proinflammatory cytokines of infection within 4-6 hours. Neutrophil CD64 integrates function involving both innate and adaptive immune responses. The aim of this review is to present literature about nCD64 as a diagnostic and prognostic marker in patients with sepsis/septic shock.
BACKGROUND
BACKGROUND
The authors searched articles over 13 years, i.e., from 2006 to 2019. They included articles written in English only and further reviewed the reference list of selected articles to obtain potentially relevant articles. Reviews, letters, commentaries, correspondences, case reports, conference abstracts, expert opinions, editorials, and animal experiments were excluded. Articles involving pediatric patients (≤18 years) were also excluded.
REVIEW RESULTS
RESULTS
Several studies have indicated that nCD64 is a highly sensitive and specific marker for the diagnosis of sepsis. Various combinations of biomarkers have been used with nCD64 for a better diagnostic value. Neutrophil CD64 as a prognostic marker in critically ill patients needs to be explored more. Most of the existing literatures have highlighted its prognostic utility based on single value at enrolment. There are limited literatures on prognostic implications of serial trend and kinetics of nCD64.
CONCLUSION
CONCLUSIONS
Neutrophil CD64 is a useful diagnostic and prognostic marker of sepsis in critically ill patients. Additional studies are needed on nCD64 in sepsis based on sepsis-3 criteria. Further trials with large sample size are needed to establish prognostic implications of serial nCD64 trend.
HOW TO CITE THIS ARTICLE
UNASSIGNED
Patnaik R, Azim A, Agarwal V. Neutrophil CD64 a Diagnostic and Prognostic Marker of Sepsis in Adult Critically Ill Patients: A Brief Review. Indian J Crit Care Med 2020;24(12):1242-1250.
Identifiants
pubmed: 33446980
doi: 10.5005/jp-journals-10071-23558
pmc: PMC7775945
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1242-1250Informations de copyright
Copyright © 2020; Jaypee Brothers Medical Publishers (P) Ltd.
Déclaration de conflit d'intérêts
Source of support: Nil Conflict of interest: None
Références
Arch Pathol Lab Med. 2006 May;130(5):654-61
pubmed: 16683883
J Immunol Methods. 2007 Jan 30;319(1-2):1-5
pubmed: 17174972
Indian J Crit Care Med. 2018 Aug;22(8):569-574
pubmed: 30186006
Eur J Intern Med. 2017 Nov;45:46-50
pubmed: 28965741
Crit Care. 2010;14(1):R15
pubmed: 20144219
Am J Respir Crit Care Med. 2012 Jul 1;186(1):65-71
pubmed: 22538802
J Clin Microbiol. 2009 Dec;47(12):3914-9
pubmed: 19846647
J Infect Dev Ctries. 2016 Mar 31;10(3):260-8
pubmed: 27031458
Clin Infect Dis. 2014 Mar;58(6):820-9
pubmed: 24363321
J Med Biochem. 2015 Oct;34(4):431-439
pubmed: 28356852
Int J Immunopathol Pharmacol. 2008 Jan-Mar;21(1):43-9
pubmed: 18336730
Clin Chem Lab Med. 2013 Apr;51(4):897-905
pubmed: 23045384
Blood. 1997 Oct 15;90(8):3187-94
pubmed: 9376602
Eur J Clin Microbiol Infect Dis. 2011 Jul;30(7):845-52
pubmed: 21249409
Thromb Res. 2008;121(4):499-507
pubmed: 17597188
J Infect. 2010 May;60(5):313-9
pubmed: 20206205
J Glob Infect Dis. 2018 Apr-Jun;10(2):42-46
pubmed: 29910563
Cytokine. 2006 Dec;36(5-6):283-90
pubmed: 17368039
Int J Lab Hematol. 2016 Oct;38(5):576-84
pubmed: 27565453
Cytometry B Clin Cytom. 2005 May;65(1):1-5
pubmed: 15800882
Eur J Clin Microbiol Infect Dis. 2016 Sep;35(9):1411-6
pubmed: 27240938
Diagn Microbiol Infect Dis. 2015 Jul;82(3):234-9
pubmed: 25921729
Clin Chem Lab Med. 2009;47(8):903-16
pubmed: 19642859
Int J Infect Dis. 2013 Jan;17(1):e12-23
pubmed: 22940278
PLoS One. 2016 Mar 22;11(3):e0152065
pubmed: 27003588
J Crit Care. 2018 Feb;43:139-142
pubmed: 28898742
Respirology. 2011 Jan;16(1):152-60
pubmed: 20946336
J Int Med Res. 2019 Sep;47(9):4304-4311
pubmed: 31319721
Intensive Care Med. 2012 Mar;38(3):445-52
pubmed: 22310872
Clin Exp Immunol. 2008 Oct;154(1):87-97
pubmed: 18727624
Acad Emerg Med. 2011 Aug;18(8):807-15
pubmed: 21762470
Shock. 2003 Jan;19(1):5-12
pubmed: 12558136
Ann Intensive Care. 2019 Jan 8;9(1):5
pubmed: 30623257
Crit Care. 2015 Jun 10;19:245
pubmed: 26059345
Intensive Care Med. 2017 Mar;43(3):304-377
pubmed: 28101605
Clin Chem Lab Med. 2015 Mar;53(4):e89-91
pubmed: 25324452
Int J Clin Exp Pathol. 2014 Oct 15;7(11):7806-13
pubmed: 25550820